Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright

Key Points

• HC Wainwright has reduced the price target for Keros Therapeutics (NASDAQ:KROS) from $25.00 to $20.00, but maintains a "buy" rating, indicating a potential upside of approximately 49.94% from the current stock price.
• Other analysts have also adjusted their ratings on Keros Therapeutics, with Bank of America downgrading the stock from "buy" to "neutral" and lowering its price target to $18.00.
• Keros' recent earnings report revealed a significant revenue increase, reporting $0.02 million compared to analyst expectations of $3.83 million, reflecting a year-over-year revenue growth of 49002.7%.

Keros Therapeutics (NASDAQ:KROS - Free Report) had its target price lowered by HC Wainwright from $25.00 to $20.00 in a research report report published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

KROS has been the subject of several other research reports. Wedbush restated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank cut their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Finally, Bank of America lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded up $0.34 during trading on Friday, reaching $13.69. The company had a trading volume of 159,790 shares, compared to its average volume of 998,925. The firm's fifty day moving average is $14.00 and its 200 day moving average is $12.81. The firm has a market capitalization of $555.88 million, a PE ratio of 44.16, a price-to-earnings-growth ratio of 1.80 and a beta of 1.33. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.38. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%. The firm's quarterly revenue was up 49002.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.25) earnings per share. Equities analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its holdings in shares of Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock valued at $692,000 after acquiring an additional 7,146 shares during the period. Franklin Resources Inc. grew its position in Keros Therapeutics by 245.5% during the 2nd quarter. Franklin Resources Inc. now owns 132,301 shares of the company's stock worth $1,766,000 after purchasing an additional 94,006 shares in the last quarter. Creative Planning raised its stake in Keros Therapeutics by 40.2% during the 2nd quarter. Creative Planning now owns 24,226 shares of the company's stock valued at $323,000 after purchasing an additional 6,948 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after purchasing an additional 1,892 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Keros Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 829,297 shares of the company's stock worth $11,073,000 after buying an additional 23,112 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.